Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06587035

A Study to Learn About Somatrogon in Patients With Pediatric Growth Hormone Deficiency (p GHD) in India.

A Multicenter, Non-interventional Prospective Active Surveillance Study Among Participants Receiving Somatrogon Under Routine Clinical Care in India

Status
Recruiting
Phase
Study type
Observational
Enrollment
50 (estimated)
Sponsor
Pfizer · Industry
Sex
All
Age
3 Years – 17 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to learn about the safety of Somatrogon for the treatment of pediatric growth hormone deficiency (p GHD) in India. Pediatric GHD is a condition caused by too less amounts of growth hormone in the body. Children with GHD have a short height. GHD can be present at birth or develop later. The condition occurs if the pituitary gland makes too little growth hormone. This is a small gland at the bottom of the brain that releases hormones that affect growth and other body functions. This study is seeking for participants who are: * confirmed with p GHD. * given Somatrogon to be taken as an injection. The safety of Somatrogon injection will be checked based on side effects. These side effects can happen within 3 years after taking Somatrogon. A side effect is something (expected or unexpected) that you feel was caused by a medicine or treatment you take. The study doctor will collect side effect information and put the information on patient's case form. Follow-up of the patient's will be performed via clinic re-visit or over a call. It is not a rule for the participants to visit the clinic in this study. This study will help to see if Somatrogon is safe.

Conditions

Interventions

TypeNameDescription
DRUGSomatrogonLong-acting growth hormone for pediatric growth hormone deficiency.

Timeline

Start date
2025-01-30
Primary completion
2026-09-21
Completion
2028-09-05
First posted
2024-09-19
Last updated
2026-01-07

Locations

4 sites across 1 country: India

Regulatory

Source: ClinicalTrials.gov record NCT06587035. Inclusion in this directory is not an endorsement.